EG 427

At EG427 our unique, non-replicative Herpes Simplex Virus type 1 (HSV-1) based vector platform called HERMES, delivers, with pinpoint precision, highly selective, durable expression of disease modifying transgenes to address prevalent diseases in neurology. Our lead asset EG110A, for the treatment of neurogenic bladder dysfunction, has received IND clearance in June 2024 from the US FDA. Our revolutionary approach to the treatment of this disease aims at providing patients with a comprehensive, long-term solution to their bladder management, through a highly selective molecular biology approach overcoming the drawbacks of current standard of care. Our HQ and labs are in Paris, France, where we were founded in 2019. We have raised over USD 21 million, including from our Series A in 2021.